

Policy Tracker Archive

116th United States Congress (January 3rd, 2019 – January 3rd, 2021)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Accountability and Oversight	Allow government to regulate/require disclosure of patient assistance	[Fair Care Act of 2020; Introduced 10/05/2020] Allow the Secretary of HHS to establish a mechanism to regulate drug manufacturers' financial contributions to patient out-of-pocket costs, such as copays.	Sen. Braun (R-IN)
Accountability and Oversight	Ensure 340B program is providing care for the low-income patients it is intended to serve	[Fair Care Act of 2020; Introduced 10/05/2020] Require DSH hospital covered entities to report on low-income utilization rates of outpatient hospital services under 340B.	Sen. Braun (R-IN)
Accountability and Oversight	Ensure biosimilars cannot be paid more than their reference biologic product	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Ensure biosimilars cannot be paid more than their reference product during the initial period.	Rep. Walden (R-OR)
Accountability and Oversight	Establish drug pricing review board/committee	[Prescription Drug Affordability and Access Act; Introduced 01/08/2020] Establish an independent bureau within HHS devoted to obtaining lower prescription drug costs for patients, decrease government spending on such drugs, and ensure adequate access. Bureau will regularly conduct reviews of prescription drug prices including certain price increases.	Sen. Booker (D-NJ)
Accountability and Oversight	Establish evidence-based measures of quality	[Medicare Prescription Drug Savings and Choice Act of 2019; Introduced 10/21/2019] Establish role of AHRQ to assess the clinical benefit of covered Part D drugs and make recommendations to the Secretary regarding negotiated prices of covered drugs.	Rep. Schakowsky (D-IL)
Accountability and Oversight	Establish evidence-based measures of quality	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Establish evidence-based measures of pharmacy quality to ensure that the incentive payments or price concessions that are paid by a pharmacy to a PDP sponsor for covered part D drugs focus on aspects of patient health outcomes that the pharmacy has an impact on.	Sen. Grassley (R-IA)
Accountability and Oversight	Health Plan Transparency	[PBM Transparency in Prescription Drug Costs Act; Introduced 12/04/2019] Amend title XXVII of the Public Health Service Act to require health plan oversight. Prohibit a group health plan or PBM from entering into	Rep. Schrader (D-OR)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		a contract with a manufacturer, distributor, wholesaler, or any other third party that limits the disclosure of information for production of reports that increase transparency.	
Accountability and Oversight	Health Plan Transparency	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Requires the reporting of any potential fraud, waste, and abuse to the Secretary of Health and Human Services by Prescription Drug or Medicare Advantage Prescription Drug plans.	Sen. Grassley (R-IA)
Accountability and Oversight	Health Plan Transparency	[A bill to increase transparency and access to group health plan and health insurance issuer reporting, and for other purposes.; Introduced 12/21/2020] Require all group insurance plans or insurers (excluding Church Plans) to report information on the past year's pharmacy benefits and drug costs to the Secretary of Labor and the Secretary of the Treasury.	Sen. Braun (R-IN)
Accountability and Oversight	Manufacturer Transparency	[Right Rebate Act of 2019; Introduced 01/24/2019] Amend the Social Security Act to stop the misclassifications of drugs that are a part of the Medicaid drug rebate program.	Sen. Wyden (D-OR)
Accountability and Oversight	Manufacturer Transparency	[Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019; Introduced 02/13/2019] Amend title XI of the Social Security Act to require drug manufacturers that increase their wholesale cost beyond a certain threshold to submit a written justification of that increase to CMS. This justification will be summarized and published on the CMS website. Manufacturers that do not abide by this bill will be fined.	Sen. Wyden (D-OR)
Accountability and Oversight	Manufacturer Transparency	[Prescription Drug STAR Act; Introduced 04/08/2019] Amend titles XI and XVIII of the Social Security Act to require manufacturers to justify certain drug price increases. Publicly disclose discounts and price concessions passed through to plan sponsors on the HHS website. Require certain manufacturers to report drug pricing information related to drugs covered under the Medicare program.	Rep. Neal (D-MA)
Accountability and Oversight	Manufacturer Transparency	[More Efficient Tools to Realize Information for Consumers Act; Introduced 04/12/2019]	Rep. Schakowsky (D-IL)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		Amend the Social Security Act to require prescription drug marketing sample information reported by manufacturers to be available to oversight agencies, researchers, and payers.	
Accountability and Oversight	Manufacturer Transparency	[More Efficient Tools to Realize Information for Consumers Act; Introduced 04/12/2019] Amend Title III of the Public Health Service Act to require manufacturers to justify certain drug price increases. Report for justification required when qualifying drug increases 10 percent or more within a single calendar year or 25 percent or more within three consecutive calendar years.	Rep. Schakowsky (D-IL)
Accountability and Oversight	Manufacturer Transparency	[Drug-price Transparency in Communications (DTC) Act; Introduced 05/13/2019] Amend title XI of the Social Security Act to require direct-to-consumer advertisements for prescription drugs and biologicals to include truthful and non-misleading pricing information.	Sen. Durbin (D-IL)
Accountability and Oversight	Manufacturer Transparency	[Prescription Drug Price Reporting Act; Introduced 05/23/2019] Require manufacturers to report a prescription drug price's wholesale acquisition cost, average net price, and rebates to health insurance plans or PBMs with respect to covered individuals.	Sen. Scott (R-FL)
Accountability and Oversight	Manufacturer Transparency	[Empowering States to Address Drug Costs Act; Introduced 07/24/2019] Amend title XIX of the Social Security Act to review AMP, best price, and rebate calculation data to establish State all-payer prescription drug rate setting entities or State multi-payer purchasing tools.	Sen. Van Hollen (D-MD)
Accountability and Oversight	Manufacturer Transparency	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Require manufacturers that do not have a Medicaid drug rebate agreement to report ASP information to the HHS to help establish Medicare payment rates.	Sen. Grassley (R-IA)
Accountability and Oversight	Manufacturer Transparency	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Amend the Social Security Act to require manufacturers to report to HHS information and supporting documentation needed to justify price increases for prescription drugs and biological products as measured by	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		wholesale acquisition cost (WAC) or changes in WAC that exceed certain thresholds.	
Accountability and Oversight	Manufacturer Transparency	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Amend the Social Security Act to require HHS Secretary to audit price and drug product information reported by manufacturers to ensure accuracy and timeliness. Allow Secretary to impose civil monetary penalties on wholesalers, manufacturers, or direct sellers if entities refuse to provide pricing information.	Sen. Grassley (R-IA)
Accountability and Oversight	Manufacturer Transparency	[CURE High Drug Prices Act; Introduced 08/02/2019] Allow the Secretary of HHS to notify a manufacturer of its potential price gouging and require a justification of the increase.	Rep. Pingree (D-ME)
Accountability and Oversight	Manufacturer Transparency	[Prescription Drug Price Reporting Act; Introduced 11/21/2019] Require manufacturers to report on each drug marketed in the U.S. their current wholesale acquisition cost, average wholesale acquisition cost during the previous calendar year, average net price, as well as total rebates during the previous calendar year or time that the drug has been marketed. Require manufacturers to report increases or decreases in wholesale acquisition cost of a prescription drug no later than 30 days before the price change takes effect.	Rep. Joyce (R-OH)
Accountability and Oversight	Manufacturer Transparency	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Require manufacturers to report drug pricing information with respect to drugs under Medicare. Require HHS to report on accuracy of ASP information submitted by manufacturers to Congress.	Rep. Walden (R-OR)
Accountability and Oversight	Manufacturer Transparency	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Ensure the accuracy of the manufacturer price and product information under Medicaid by conducting audits and surveys.	Rep. Walden (R-OR)
Accountability and Oversight	Manufacturer Transparency	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Require manufacturers to justify certain drug price increases.	Rep. Walden (R-OR)
Accountability and Oversight	Manufacturer Transparency	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Improvement	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		of manufacturer reporting of ASP in order to set more accurate payment rates.	
Accountability and Oversight	Manufacturer Transparency	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Require drug manufacturer price transparency for drugs with a large price increase, high spending, or high launch price (for new drugs).	Sen. Grassley (R-IA)
Accountability and Oversight	PBM Transparency	[Prescription Drug Price Transparency Act; Introduced 02/07/2019] Establish standards for pharmacy benefits manager under the Medicare prescription drug program and Medicare Advantage program to further transparency of payment methodologies to pharmacies, and for other purposes.	Rep. Collins (R-GA)
Accountability and Oversight	PBM Transparency	[Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; Introduced 02/13/2019] Amend titles XI and XVIII of the Social Security Act to increase transparency of discounts provided by drug manufacturers by publicly disclosing PBMs' ability to negotiate rebates, discounts, and price concessions and the amounts passed through to plan sponsors.	Sen. Wyden (D-OR)
Accountability and Oversight	PBM Transparency	[Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act; Introduced 04/08/2019] Amend titles XI and XVIII of the Social Security Act to require public disclosure of rebates, discounts, remuneration fees, administrative fees, and price concessions and the amounts passed through to plan sponsors.	Rep. Spanberger (D-VA)
Accountability and Oversight	PBM Transparency	[More Efficient Tools to Realize Information for Consumers Act; Introduced 04/12/2019] Amend the Social Security Act to make publicly available PBMs' ability to negotiate rebates, discounts, remuneration fees, administrative fees, and price concessions as well as the amounts passed on to plan sponsors.	Rep. Schakowsky (D-IL)
Accountability and Oversight	PBM Transparency	[Phair Relief Act of 2019; Introduced 07/24/2019] Amend titles XI and XVIII of the Social Security Act to make PBMs' ability to negotiate rebates, discounts, and price concessions as well as their amounts publicly available through the HHS website.	Sen. Kennedy (R-LA)
Accountability and Oversight	PBM Transparency	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Require HHS to publicly report information	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		on aggregate price concessions, difference between what insurer pays PBM and what PBM pays pharmacies, and number of prescriptions dispensed while still preventing disclosure of price concessions for specific plans or drugs. Require Part D insurers to conduct financial audits of data related to their PBM contracts. Require Part D insurers to report to pharmacies' post-point-of-sales adjustments for price concessions or incentive payments for covered Part D drugs. Require Part D insurers to report actual and projected direct and indirect remuneration amounts in bids for Part D coverage.	
Accountability and Oversight	PBM Transparency	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Establishes audits of PBM managers and data.	Sen. Grassley (R-IA)
Accountability and Oversight	PBM Transparency	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Strengthen pharmacy benefit managers' transparency requirements.	Sen. Grassley (R-IA)
Accountability and Oversight	PBM Transparency	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Requires disclosure of pharmacy price concessions for covered part D drugs.	Sen. Grassley (R-IA)
Accountability and Oversight	Provide evidence of clinical superiority to receive financial rewards	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Clarify that in order to get new exclusivities, all orphan drugs must prove clinical superiority to a previous version of the drug already on the market.	Rep. Walden (R-OR)
Accountability and Oversight	Provider Transparency	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Improving claims data that is provided to prescription drug plans to encourage appropriate use of medications and improve health outcomes.	Sen. Grassley (R-IA)
Foster Competition	Drug importation for noncompetitive markets	[Executive Order on Increasing Drug Importation to Lower Prices for American Patients; Introduced 07/24/2020] Permitting the importation of prescription drugs from other countries in order to create more competition in domestic pricing and lower the cost of prescription drugs for Americans.	President Donald Trump
Foster Competition	Incentivize generic and biosimilar entry	[CREATES Act of 2019; Introduced 02/05/2019] Promote the competition in the drug market by facilitating the entry of lower-cost generic and biosimilar versions of drugs.	Sen. Leahy (D-VT)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Foster Competition	Incentivize generic and biosimilar entry	[Fair Care Act of 2019; Introduced 02/25/2019] Expedite development and priority review for generic complex drug products.	Rep. Westerman (R-AZ)
Foster Competition	Incentivize generic and biosimilar entry	[Competition Prescription Act of 2019; Introduced 07/24/2019] Expedite development and priority review for complex generic drugs.	Rep. Meadows (R-NC)
Foster Competition	Incentivize generic and biosimilar entry	[BIOSIM Act; Introduced 09/20/2019] Amend title XVIII of the Social Security Act to temporarily increase payment under Medicare program for certain biosimilars to incentivize biosimilar development.	Rep. Schrader (D-OR)
Foster Competition	Incentivize generic and biosimilar entry	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Change the conditions of first generic exclusivity to spur access and competition.	Rep. Walden (R-OR)
Foster Competition	Incentivize generic and biosimilar entry	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Streamline biosimilars approval process by providing clarity for applicants that they can include information in their application showing the proposed conditions of use have been previously approved for the reference product.	Rep. Walden (R-OR)
Foster Competition	Incentivize generic and biosimilar entry	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Require prescription drug marketing sample information reported by manufacturers to be available to certain individuals and entities.	Rep. Walden (R-OR)
Foster Competition	Incentivize generic and biosimilar entry	[Fair Care Act of 2020; Introduced 10/05/2020] Expedite development and priority review for generic complex drugs.	Sen. Braun (R-IN)
Foster Competition	Incentivize use of biosimilars and generics	[FAST Generics Act of 2019; Introduced 02/05/2019] Amend the Federal Food, Drug, and Cosmetic Act to allow sponsors interested in developing generic drugs and biosimilars to have competitive access to currently approved drugs and licensed biological products.	Rep. Welch (D-VT)
Foster Competition	Incentivize use of biosimilars and generics	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/5/2019] Increase add-on payment for a biosimilar under Medicare Part B from 6% of reference product's ASP to 8% for a period of five years.	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Foster Competition	Incentivize use of biosimilars and generics	[Star Rating for Biosimilars Act; Introduced 10/08/2019] Amend title XVIII of the Social Security Act to implement new set of measures in the 5-star rating system under the Medicare Advantage program to encourage increased access to biosimilar products. Measures include coverage on plan formularies, tier placement, utilization management tools, and utilization relative to the reference biological product.	Rep. Tonko (D-NY)
Foster Competition	Incentivize use of biosimilars and generics	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] A temporary increase in Medicare Part B payments for biosimilars.	Sen. Grassley (R-IA)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Preserve Access to Affordable Generics and Biosimilars Act; Introduced 01/09/2019] Prohibits brand name drug companies from paying generic drug companies for delaying the entry of a generic drug in the market. Similarly, prohibits biological product manufacturers from paying biosimilar companies to delay entry of biosimilar products	Sen. Klobuchar (D-MN)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Prescription Drug Price Relief Act of 2019; Introduced 01/10/2019] End government-granted monopolies for drug manufacturers who charge prices that are higher than the median price charged in other countries.	Sen. Sanders (I-VT)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[PACED Act; Introduced 02/12/2019] Amend title 35 to prohibit patent owners from asserting sovereign immunity as a defense before the U.S. Patent & Trademark Office to prevent the production of generics.	Sen. Cotton (R-AR)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Further Consolidated Appropriations Act, 2020; Introduced 03/25/2019] Promote competition by applying limitations on branded biologic exclusivity and not granting additional exclusivity through deeming. Prevent drug manufacturers from abusing REMS and restricting generic and biosimilar competition.	Rep. Pascrell (D-NJ)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Stop STALLING Act; Introduced 04/29/2019] Deter the filing of sham citizen petitions that attempt to interfere with the approval of a competing generic drug or biosimilar.	Sen. Klobuchar (D-MN)
Foster Competition	Limit anticompetitive	[Affordable Prescriptions for Patients Act of 2019; Introduced 05/09/2019] Amend the	Sen. Cornyn (R-TX)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
	behaviors by manufacturers	Federal Trade Commission Act to prohibit anticompetitive behaviors by drug manufacturers, including "product hopping."	
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Affordable Prescriptions for Patients Through Promoting Competition Act of 2019; Introduced 09/19/2019] Amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug manufacturers, including "product hopping."	Rep. Cicilline (D-RI)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Allow for actions against bad actors who delay generics and biosimilars coming to market by withholding drug samples.	Rep. Walden (R-OR)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Prevent manufacturers from gaming the system by receiving additional exclusivity periods once they are deemed biologics.	Rep. Walden (R-OR)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020; Introduced 03/03/2020] Preserve access to affordable generics and biosimilars by allowing the Commission to initiate a proceeding against agreements presumed to have anticompetitive effects.	Sen. McSally (R-AZ)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Fair Care Act of 2020; Introduced 10/05/2020] Prohibit agreements that would prevent generic applicants from commercial marketing upon approval.	Sen. Braun (R-IN)
Foster Competition	Limit anticompetitive behaviors by manufacturers	[Fair Care Act of 2020; Introduced 10/05/2020] Prohibit civil petitions with the intent of delaying generic entry.	Sen. Braun (R-IN)
Foster Competition	Reduce market monopoly	[Prescription Drug Price Relief Act of 2019; Introduced 01/10/2019] End government-granted monopolies in regards to manufacturers who price drugs higher than the median in other countries	Sen. Sanders (I-VT)
Foster Competition	Reduce market monopoly	[Fair Care Act of 2019; Introduced 02/25/2019] Limit exclusivity periods for drugs that treat rare diseases and conditions.	Rep. Westerman (R-AZ)
Foster Competition	Reduce market monopoly	[Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act; Introduced 05/14/2019] Incentivize low-cost drug options by changing the conditions of first-	Rep. Burgess (R-TX)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		filer generic exclusivity to encourage competition.	
Foster Competition	Reduce market monopoly	[PRICED Act; Introduced 06/20/2019] Amend the Public Health Service Act to shorten exclusivity period for brand name biological products from 12 to 5 years.	Rep. Schakowsky (D-IL)
Foster Competition	Reduce market monopoly	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Limit potential for "evergreening" by restricting manufacturers from obtaining new exclusivities on previously approved clinical entities.	Rep. Walden (R-OR)
Foster Competition	Reduce market monopoly	[To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products, and for other purposes.; Introduced 03/09/2020] Amend the Biologics Price Competition and Innovation Act of 2009 by listing certain insulin products as interchangeable biosimilars.	Rep. Grothman (R-WI)
Foster Competition	Reduce market monopoly	[Fair Care Act of 2020; Introduced 10/05/2020] Consolidate exclusivity periods for drugs treating rare diseases by not allowing the Secretary to approve a different applicant or issue a license for the same drug for the same disease until the original exclusivity period expires.	Sen. Braun (R-IN)
Foster Competition	Reduce market monopoly	[Fair Care Act of 2020; Introduced 10/05/2020] Protect access to biologics by limiting additional exclusivities.	Sen. Braun (R-IN)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[Transparent Drug Pricing Act of 2019; Introduced 04/01/2019] Amend the Social Security Act to require disclosure of drug prices at point of sale, including customer's out-of-pocket cost in context of current health plan as well as cost without using any health plan. HHS required to make this information publicly available through a database that allows consumers to subscribe to price change notifications for prescription drugs.	Sen. Scott (R-FL)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act; Introduced 04/08/2019] Require prescription drug plan sponsors to include real-time benefit information as part of sponsor's electronic prescription program under Medicare.	Rep. Spanberger (D-VA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[More Efficient Tools to Realize Information for Consumers Act; Introduced 04/12/2019] Amend the Social Security Act to require prescription drug plan sponsors to include real-time benefit information as part of the sponsor's electronic prescription program under Medicare. Information should include clinically appropriate alternatives to drugs in formulary, cost-sharing information, and applicable utilization management requirements.	Rep. Schakowsky (D-IL)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Modify transparency tool provision to require comparable information for services that can also be furnished in a physician office.	Sen. Grassley (R-IA)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Require Part D insurers to provide for a "real-time benefit tool (RTBT)" that enables electronic transmission formulary and benefit information to each enrollee's prescribing clinician.	Sen. Grassley (R-IA)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Require prescription drug plan sponsors to include real-time benefit information as part of sponsor's electronic prescription program under Medicare.	Rep. Walden (R-OR)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[Lowest Price for Patients Act; Introduced 12/16/2019] Amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire the drug.	Rep. Porter (D-CA)
Increase price awareness throughout the supply chain	Disclosure of pricing information to beneficiaries at decision-making	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Requiring Medicare Advantage Organizations and Prescription Drug Plans to increase the use of real-time benefit information and tools for prescribers by incorporating such tools into electronic health record systems.	Sen. Grassley (R-IA)
Increase price awareness	Public disclosure of pricing information	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Require public disclosure of drug discounts on the internet	Rep. Walden (R-OR)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
throughout the supply chain		in order to allow comparison of PBMs' ability to negotiate rebates, discounts, remuneration fees, concessions, etc.	
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Codify recent HHS regulations to require pharmaceutical companies to list prices of their prescription drugs in direct-to-consumer advertisements.	Rep. Walden (R-OR)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Transparency in Prescription Drug Advertising Act; Introduced 02/13/2020] Urge the Secretary of HHS to require the list prices of drugs to be included in advertisements.	Rep. Davids (D-KS)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Transparency and Accountability in Health Care Costs and Prices Act of 2020; Introduced 02/27/2020] Amend title XXVII of the Public Health Service Act to require the Secretary of Health and Human Services to establish a grant program facilitating State efforts to establish or maintain an all-payer claims databases (APCD) in order to increase transparency. APCD data allows for users to track trends in health care prices, check price and quality, and aid employers and health plans in making informed decisions when developing health plans.	Rep. Lipinski (D-IL)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Make PBM provisions and drug discounts available on the internet in order to allow patients and employers to compare PBMs' ability to negotiate rebates, discounts concessions, etc.	Sen. Grassley (R-IA)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Establish prescription drug pricing dashboards to be publicly available on the internet for beneficiaries, clinicians, researchers, and the public to view information on utilization and spending on prescription drugs and biologics covered under Medicare parts B, D, and Medicaid.	Sen. Grassley (R-IA)
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Increasing the transparency of the Medicare website by expanding the information published to include the amount paid to the physician for an item or service and the estimated amount	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		of that the beneficiary pays for the item or service.	
Increase price awareness throughout the supply chain	Public disclosure of pricing information	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Requires that the results of remuneration reports be disclosed to the public online for all prescription drug plans.	Sen. Grassley (R-IA)
Limit Price Inflation	Adjusting payments for inflation	[Competition Prescription Act of 2019; Introduced 07/24/2019] Allow Secretary of HHS to alter payments for prescription drugs provided through Medicare Part B by paying rates that are adjusted for inflation.	Rep. Meadows (R-NC)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[Stop Price Gouging Act; Introduced 02/07/2019] Impose an excise tax on pharmaceutical companies that sell prescription drugs subject to price spikes that exceed rates of inflation.	Sen. Brown (D-OH)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[Stop Price Gouging Act; Introduced 02/07/2019] Subject pharmaceutical companies to an excise tax if drug prices exceed the annual percentage increase in the Chained Consumer Price Index.	Sen. Brown (D-OH)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[Stop Drug Companies from Overcharging Seniors in Medicare Part B Act of 2019; Introduced 07/10/2019] Amend title XVIII of the Social Security Act to require manufacturers to provide rebates for drugs covered under Medicare Part B if growth in average sales price exceeds inflation.	Sen. Peters (D-MI)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Require drug manufacturers to pay a rebate to Medicare for the amount their Part B drugs increase above the rate of inflation.	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Establish a mandatory rebate if a pharmaceutical manufacturer increases their list price for certain covered Part D drugs above inflation.	Sen. Grassley (R-IA)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[CURE High Drug Prices Act; Introduced 08/02/2019] Grant the Secretary the power to also restore any excessive amount paid from the price increase to the consumer or the payer.	Rep. Pingree (D-ME)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[Pharmaceutical REPAI Act; Introduced 10/08/2019] Amend title XVIII of the Social Security Act to require drug manufacturers to pay a Medicare Part D rebate for certain drugs if the price increases above the rate of inflation.	Rep. Schakowsky (D-IL)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Establishment of Medicare Part B rebates for drugs and biologics with prices that are increasing faster than inflation.	Sen. Grassley (R-IA)
Limit Price Inflation	Impose a financial disincentive on manufacturers for drug prices that are increasing faster than inflation. Examples include excise taxes and rebates.	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Amendment to the Social Security Act that requires manufacturer rebates for Medicare Part D drugs with prices that are increasing faster than inflation.	Sen. Grassley (R-IA)
Limit Price Inflation	Reduce period of exclusivity	[FLAT Prices Act; Introduced 02/06/2019] Reduce the period of exclusivity of prescription drugs if there is an increase in	Sen. Durbin (D-IL)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		the wholesale acquisition cost beyond a set threshold.	
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Affordable and Safe Prescription Drug Importation Act; Introduced 01/10/2019] Amend the Federal Food, Drug, and Cosmetic Act for the importation of safe drugs.	Rep. Cummings (D-MD)
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Safe Importation Action Plan; Introduced 07/31/2019] Lay the foundation for the safe importation of certain drugs from foreign countries by: 1) authorizing demonstration projects allowing for the importation of drugs from Canada and 2) allowing manufacturers to import versions of FDA-approved drugs they sell in foreign markets.	Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA)
Reduce costs and improve access for patients	Allow for the importation of FDA-approved drugs from other countries	[Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020; Introduced 03/03/2020] Allow individuals to import prescription drugs from Canada. Individuals may purchase drugs for personal use from approved Canadian pharmacies using a valid prescription issued by a physician licensed to practice in the United States.	Sen. McClellan (R-AZ)
Reduce costs and improve access for patients	Alternative payment plans	[Lower Costs, More Cures Act of 2019; Introduced 12/19/2019] Allow certain enrollees of prescription drug plans and MA-PD plans under Medicare to spread out cost-sharing.	Rep. Walden (R-OR)
Reduce costs and improve access for patients	Incentivize physician prescribing of lower cost drugs	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Vary payment for certain drugs covered under Medicare Part B to incentivize providers to utilize lower cost drugs.	Rep. Walden (R-OR)
Reduce costs and improve access for patients	Include price concessions in point-of-sale (POS) for patients enrolled in Medicare/Medicaid	[Pharm Pricing Act of 2019; Introduced 02/07/2019] Amend the Social Security Act to require that pharmacy-negotiated price concessions are factored into the negotiated prices at point-of-sale for Medicare Part D program.	Rep. Collins (R-GA)
Reduce costs and improve access for patients	Include price concessions in point-of-sale (POS) for patients enrolled in Medicare/Medicaid	[Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; Introduced 02/13/2019] Require negotiated prices for Part D covered drugs to be provided at point-of-sale.	Sen. Wyden (D-OR)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs and improve access for patients	Include price concessions in point-of-sale (POS) for patients enrolled in Medicare/Medicaid	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Include incentives to provide a share of rebates at the point-of-sale.	Rep. Walden (R-OR)
Reduce costs and improve access for patients	Include price concessions in point-of-sale (POS) for patients enrolled in Medicare/Medicaid	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Requires pharmacy negotiated price concessions, payments, and fees to be included in the negotiating price at point-of-sale under Medicare part D.	Sen. Grassley (R-IA)
Reduce costs and improve access for patients	Increase beneficiary choices under Medicare	[Keeping Health Insurance Affordable Act of 2019; Introduced 01/03/2019] Amend the Social Security Act to ensure that each Part D eligible individual has a choice of at least three plans in the area in which the individual resides.	Sen. Cardin (D-MD)
Reduce costs and improve access for patients	Increasing manufacturer rebates to government programs	[Keeping Health Insurance Affordable Act of 2019; Introduced 01/03/2019] Require manufacturers to provide rebates to CMS for drugs administered to low-income patients.	Sen. Cardin (D-MD)
Reduce costs and improve access for patients	Increasing manufacturer rebates to government programs	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Inclusion of discounts to purchasers and individuals in the calculation of average sales price for drugs and biologics included in Medicare Part B, excluding in-kind donations to low income patients.	Sen. Grassley (R-IA)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[RxCAP Act of 2019; Introduced 02/13/2019] Prevent catastrophic out-of-pocket spending on prescription drugs for seniors and individuals with disabilities, capping spending at \$7,500 for Part D beneficiaries.	Sen. Wyden (D-OR)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Prescription Drug Rebate Reform Act of 2019; Introduced 05/09/2019] Amend the Public Health Service Act to require a group health plan or insurer to set coinsurance for a prescription drug based on the drug's net price instead of the list price.	Sen. Romney (R-UT)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[CLAY Act; Introduced 05/15/2019] Amend title XVIII of the Social Security Act to reduce cost-sharing for low-income individuals covered under Medicare Part D.	Rep. Cunningham (D-SC)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Change the structure of the part D benefit to	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		change enrollee cost-sharing in the initial coverage limit and coverage gap, cap enrollee cost sharing above the catastrophic threshold, and change the amount of annual out-of-pocket spending needed to reach catastrophic coverage.	
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 09/19/2019] Cap seniors' out of pocket drug expenses at \$2,000 annually.	Rep. Pallone (D-NJ)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Establish a monthly \$50 post-deductible cap for insulin and insulin supplies for seniors starting in 2022.	Rep. Walden (R-OR)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Restructure Medicare Part D benefit to institute \$3,100 annual out-of-pocket cap for beneficiaries and add 10% manufacturer responsibility throughout the benefit.	Rep. Walden (R-OR)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Provide a safe harbor for plans without a deductible for insulin by treating such plans as high deductible plans.	Rep. Walden (R-OR)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Affordable Insulin for All Act; Introduced 02/04/2020] Amend title XI of the Social Security Act to establish the American Insulin Program to require manufacturers to provide applicable individuals access to Medicaid prices for their insulin drugs. Cap out-of-pocket costs at not more than \$10 for each one-month period of coverage for insulin drugs. Include provisions that require pass-through pricing in contracts between the State and a Pharmacy Benefit Manager or managed care entity.	Rep. Crist (D-FL)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020; Introduced 03/03/2020] Reduce beneficiary coinsurance under Medicare part D.	Sen. McSally (R-AZ)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020; Introduced 03/03/2020] Establish a manufacturer discount program where the Secretary of Health and Human Services enters into agreements with manufacturers to provide applicable beneficiaries access to	Sen. McSally (R-AZ)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		discounted prices for applicable drugs under Medicare part D.	
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Part D Senior Savings Model; Introduced 03/26/2020] Cap seniors' insulin costs at \$35 a month per type of insulin under Medicare part D.	Centers for Medicare & Medicaid Services
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Reduce the part D premium.	Sen. Grassley (R-IA)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Establishes a maximum monthly cap on cost-sharing payments under both prescription drug plans and Medicare advantage prescription drug plans.	Sen. Grassley (R-IA)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Legalizing Drug Discounts for Seniors Act of 2020; Introduced 07/22/2020] Amend the Social Security Act to exclude discounts for covered part D drugs from the anti-kickback prohibition.	Sen. Paul (R-KY)
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Executive Order on Access to Affordable Life-saving Medications; Introduced 07/24/2020] Improving the financial availability of insulin and injectable epinephrine by allowing the sale of such drugs at FQHC purchase price for eligible individuals.	President Donald Trump
Reduce costs and improve access for patients	Lower out-of-pocket (OOP) costs	[Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen; Introduced 07/24/2020] Eliminating rebates to middlemen and passing those price discounts on to patients by creating new safe harbors that allow for patient directed discounts at point of sale.	President Donald Trump
Reduce costs and improve access for patients	Streamline FDA review for drugs that have already been approved in other countries	[Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019; Introduced 07/18/2019] Require the Food and Drug Administration (FDA) to quickly review drug, device, and biologic applications from sponsors who have products approved and sold in developed and trustworthy countries.	Sen. Cruz (R-TX)
Reduce costs and improve access for patients	Streamline FDA review for drugs that have already been approved in other countries	[Competition Prescription Act of 2019; Introduced 07/24/2019] Expedite licensing process for biologics that have been authorized or marketed by the European Medicines Agency.	Rep. Meadows (R-NC)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs and improve access for patients	Strengthen payer negotiating power by removing legal barriers	[State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019; Introduced 04/02/2019] Create an exemption in antitrust laws for private health insurers to jointly negotiate wholesale acquisition costs of prescription drugs from manufacturers.	Rep. Meadows (R-NC)
Reduce costs and improve access for patients	Strengthen payer negotiating power by removing legal barriers	[Competition Prescription Act of 2019; Introduced 07/24/2019] Create exemption in antitrust laws to allow health insurance issuers to jointly negotiate WAC prices of a prescription drug with a manufacturer, so long as no WAC price is jointly determined between insurance issuers.	Rep. Meadows (R-NC)
Reduce costs and improve access for patients	Strengthen payer negotiating power by removing legal barriers	[Fair Care Act of 2020; Introduced 10/05/2020] Create an antitrust exemption for private health insurers to jointly negotiate WAC prices of prescription drugs.	Sen. Braun (R-IN)
Reduce costs and improve access for patients	Utilize international reference pricing	[End Price Gouging for Medications Act; Introduced 06/26/2019] Establish annual reference prices for each prescription drug based on specific reference countries or distinct set of factors if drug pricing information not available in other countries. Require the retail list price for a drug not exceed the corresponding reference price.	Rep. Welch (D-VT)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Keeping Health Insurance Affordable Act of 2019; Introduced 01/03/2019] Allow Medicare to negotiate drug prices with manufacturers.	Sen. Cardin (D-MD)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Prescription Drug Price Negotiation Act of 2019; Introduced 01/08/2019] Allow CMS to negotiate prices for covered drugs directly with pharmaceutical companies	Rep. Welch (D-VT)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; Introduced 01/09/2019] Allow the Secretary of Health and Human Services to negotiate prescription drug prices under Part D of the Medicare program by striking the subsection of the Social Security Act that prohibits interference by the Secretary in negotiations between manufacturers, pharmacies, and plan sponsors, as well as requirements for a particular formulary or price structure for reimbursing Part D drugs.	Sen. Klobuchar (D-MN)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Drug Price Negotiation Act; Introduced 01/10/2019] Amend the Social Security Act to allow for the Secretary of HHS to negotiate part D drugs prices and the creation of a formulary for Medicare part D.	Rep. Cummings (D-MD)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Negotiation and Competitive Licensing Act of 2019; Introduced 02/07/2019] Amend the Social Security Act to require the Secretary of HHS to negotiate drugs under the Medicare Part D program.	Sen. Brown (D-OH)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 09/19/2019] Allow Medicare to negotiate prices on 25-250 of the most expensive drugs that do not face market competition per year. Minimum number of drugs negotiated increases to 30 between 2028-2032 and then increases to 35 in 2033. Apply discounts (negotiated by Medicare) to private health plans as well. Enact penalty if manufacturers refuse to participate in negotiations, starting at 65% of gross sales of drug in question.	Rep. Pallone (D-NJ)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 09/19/2019] Establish a Fair Price Negotiation Program where the Secretary enters into agreements with the manufacturers of selected drugs to negotiate for lower prices. Negotiated price may not exceed 120% of the price in six other reference countries.	Rep. Pallone (D-NJ)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Medicare Prescription Drug Savings and Choice Act of 2019; Introduced 10/21/2019] Amend title XVIII of the Social Security Act to allow Medicare to negotiate prescription drug prices under Part D.	Rep. Schakowsky (D-IL)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Life-Sustaining Prescription Drug Price Relief Act of 2019; Introduced 11/12/2019] Limit prices of life-sustaining prescription drugs by allowing the Secretary of Health and Human Services to negotiate prices under Medicare Part D. Total payment for a drug may not exceed 110 percent of the average price charged in 5 reference countries.	Rep. Lipinski (D-IL)
Reduce costs for government health programs	Allow the Medicare program to negotiate with manufacturers	[Lowering Prescription Drug Prices for America's Seniors and Families Act of 2020; Introduced 03/03/2020] Allow for the negotiation of prices for certain covered	Sen. McSally (R-AZ)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		Medicare part D drugs following period of exclusivity. If Secretary is unable to reach an agreement, use Medicaid best price.	
Reduce costs for government health programs	Alter payment rates	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Narrow the definition of "bona fide service fees," which do not have to be included by manufacturers as a concession when calculating and reporting a drug's ASP. This would effectively expand the fees that manufacturers pay to wholesalers and GPOs that must be treated as price concessions and included in the ASP.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Alter payment rates	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Remove exception for "grandfathered" off-campus HOPDs, thus establishing PFS payment rate rather than the higher OPPS payment rate. Reduced payments would lower spending and beneficiary cost-sharing.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Alter payment rates	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Sunset the current coverage gap discount program where manufacturers pay 70% of drug costs and establish a new manufacturer discount program where manufacturers provide discounts for drugs and biologics utilized during catastrophic coverage. Manufacturers that choose to have their drugs covered would enter into agreements with HHS to provide 20% off negotiated prices during catastrophic coverage.	Sen. Grassley (R-IA)
	Alter payment rates	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Require prescription manufacturers to exclude the value of coupons provided to privately insured individuals from each drug's ASP as reported to HHS.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Alter payment rates	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Require payment to pharmacy benefit manager for administrative services to be limited to a reasonable administrative fee under Medicaid, including under managed care.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Alter payment rates	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Amend the Social Security Act to provide, at	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
		the option of a state, that the term "covered outpatient drug" include any drug, biological product, or insulin as part of a bundled payment if provided on an outpatient basis and in same setting as physicians' services or outpatient hospital services.	
Reduce costs for government health programs	Alter payment rates	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Require site-neutral payment for the administration of drugs under Medicare Part B at the lower physician fee schedule rate rather than the rate paid to hospitals.	Rep. Walden (R-OR)
Reduce costs for government health programs	Alter payment rates	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Establishes that the payment amount for a covered drug administration service be the same and will apply if the drug administration service is provided by an off-campus outpatient department of the provider.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019; Introduced 02/13/2019] Require PBMs that manage prescription drug coverage under contract with a PDP sponsor or MA organization to pass through to the plan sponsor a minimum percent of the rebates, discounts, or price concessions that the PBM negotiates.	Sen. Wyden (D-OR)
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[Phair Relief Act of 2019; Introduced 07/24/2019] Require a pharmacy benefit manager (PBM) that manages prescription drug coverage under a contract with a PDP sponsor or MA organization to pass through to the plan sponsor a minimum percent of the aggregate amount of the rebates, discounts, or price concessions the PBM negotiates.	Sen. Kennedy (R-LA)
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Amend the Social Security Act to require pass-through pricing to the state for covered outpatient drugs under Medicaid, including under managed care.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated	[Drug Price Transparency in Medicaid Act of 2019; Introduced 12/03/2019] In any contract between the State and a PBM, require pass-through pricing for covered outpatient drugs.	Rep. Carter (R-GA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
	with government health programs		
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[PBM Transparency in Prescription Drug Costs Act; Introduced 12/04/2019] Require 100% of rebates, fees, and discounts Pharmacy Benefit Managers receive from manufacturers to be passed through to plan sponsor.	Rep. Schrader (D-OR)
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Improve transparency and prevent the use of abusive spread pricing in Medicaid by requiring pass-through pricing and conducting survey of retail prices.	Rep. Walden (R-OR)
Reduce costs for government health programs	Implement pass-through pricing requirement to plan sponsors associated with government health programs	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Require pass-through pricing in contracts between the State and a PBM or managed care entity under Medicaid.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.; Introduced 01/03/2019] Sunset the limit on the maximum rebate amount under Medicaid.	Rep. Burgess (R-TX)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Amend the Social Security Act to exclude authorized generics from AMP calculation for purposes of the Medicaid drug rebate program. Amend statutory definition of wholesaler to exclude COD manufacturers.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Revise the Social Security Act to increase maximum allowable Medicaid rebate permissible in a rebate period from 100% of a covered outpatient drug's AMP to 125% starting fiscal year 2022.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Continuing Appropriations Act, 2020, and Health Extenders Act of 2019; Introduced 09/18/2019] Amend the Social Security Act to exclude authorized generics from AMP calculations for Medicaid Drug Rebate purposes.	Rep. Lowey (D-NY)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Sunset the limit on the maximum rebate amounts for single source and innovator multiple source drugs.	Rep. Walden (R-OR)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Apply Medicaid drug rebate requirements to drugs provided as a part of outpatient hospital services.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Sunset limit on maximum rebate amount for single source drugs and innovator multiple source drugs under Medicaid.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Exclude authorized generics from the calculation of AMP under the Medicaid Drug Rebate Program.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Increasing manufacturer rebates to government programs	[Fair Drug Prices for Kids Act; Introduced 10/06/2020] Apply requirements of Medicaid Drug Rebate Program to cover outpatient, Part D drugs under CHIP.	Rep. Wild (D-PA)
Reduce costs for government health programs	Limiting add-on payments to providers	[Sustaining Excellence in Medicaid Act of 2019; Introduced 06/13/2019] Amend the Medicaid Program to reduce the WAC add-on payment for new drugs or biologics from 6% to 3% when ASP is unavailable.	Rep. Dingell (D-MI)
Reduce costs for government health programs	Limiting add-on payments to providers	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Establish a WAC add-on payment no greater than 3% when ASP is unavailable for new drugs.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Limiting add-on payments to providers	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Establish payment rate for initial period that is the lesser of the biosimilar's WAC plus 3% or ASP plus 6% of the reference biological product's ASP.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Limiting add-on payments to providers	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Establish \$1,000 as maximum add-on amount that a provider can be paid for a drug.	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Limiting add-on payments to providers	[Lower Costs, More Cures Act of 2019; Introduced 12/19/2019] Create maximum add-on payments for certain drugs and biologicals (\$1,000 for most drugs and \$2,000 for certain immunotherapies) to reduce out-of-pocket costs.	Rep. Walden (R-OR)
Reduce costs for government health programs	Limiting add-on payments to providers	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Limit the add-on payment amount to providers and hospitals for biosimilars during the initial period.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Limiting add-on payments to providers	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Establishment of add on payment maximums from drugs and biologics beginning on January 1, 2022.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Require rebates for amount of drug discarded for medicines packaged in single-dose vials	[REFUND Act of 2019; Introduced 02/25/2019] Require manufacturers of certain single-dose vial drugs covered under Medicare Part B to provide rebates with respect to amounts of drug discarded.	Sen. Durbin (D-IL)
Reduce costs for government health programs	Require rebates for amount of drug discarded for medicines packaged in single-dose vials	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Require manufacturer to refund the amount of payment made to providers for unused amounts of certain single-use vials under Medicare Part B.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Require rebates for amount of drug discarded for medicines packaged in single-dose vials	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Require manufacturers of certain single-dose containers or single-use package drugs under Medicare Part B to provide refunds with respect to discarded amounts of these drugs.	Rep. Walden (R-OR)
Reduce costs for government health programs	Require rebates for amount of drug discarded for medicines packaged in single-dose vials	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Requires that manufacturers of drugs under Medicare Part B that have single dose packaging provide refunds for the amount of the drug that is discarded.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Share risk between payers and manufacturers	[The Prescription Drug Pricing Reduction Act (PDPRA) of 2019; Introduced 07/25/2019] Allow states to pay for certain covered outpatient drugs in the Medicaid Drug Rebate Program through risk-sharing, value-based agreements. Enable states to use this for covered outpatient drugs that are potentially curative treatments.	Sen. Grassley (R-IA)

Purported Policy Intent	Policy Mechanisms	Proposals	Source
Reduce costs for government health programs	Share risk between payers and manufacturers	[Lower Costs, More Cures Act of 2019; Introduced 12/09/2019] Add an option for states to pay for certain covered outpatient drugs through risk-sharing value-based agreements beginning January 1, 2022.	Rep. Walden (R-OR)
Reduce costs for government health programs	Share risk between payers and manufacturers	[GENE Therapy Payment Act; Introduced 02/12/2020] Provide States with the option to pay for certain covered outpatient drugs under Medicaid by entering into risk-sharing value-based agreements with manufacturers.	Rep. Schrader (D-OR)
Reduce costs for government health programs	Share risk between payers and manufacturers	[Prescription Drug Pricing Reduction Act of 2020; Introduced 07/02/2020] Provide states with the option to pay for covered outpatient drugs that are potentially curative treatments intended for one-time use to enter into risk-sharing value-based agreements with drug manufacturers.	Sen. Grassley (R-IA)
Reduce costs for government health programs	Utilize international reference pricing	[Elijah E. Cummings Lower Drug Costs Now Act; Introduced 09/19/2019] Enact international pricing index by capping U.S. drug payments for Medicare at an average of foreign prices. Negotiated prices cannot be above 120% of drug costs in six foreign markets.	Rep. Pallone (D-NJ)
Reduce costs for government health programs	Utilize international reference pricing	[Life-Sustaining Prescription Drug Price Relief Act of 2019; Introduced 11/12/2019] Limit prices of life-sustaining prescription drugs by allowing the Secretary of Health and Human Services to negotiate prices under Medicare Part D. Total payment for a drug may not exceed 110 percent of the average price charged in 5 reference countries.	Rep. Lipinski (D-IL)